Buy, Sell or Hold? Sell-side Consensus is in on Target Corporation (NYSE:TGT), Seattle Genetics, Inc. (NASDAQ:SGEN)

June 27, 2017

Research analysts covering Target Corporation (NYSE:TGT) are projecting that the shares reach $61.846 within the next 12-18 months.  This is the consensus number derived from the 13 analyst reports taken into consideration. The most bullish, or aggressive analyst target pins the projected price at $77, while the most bearish, or conservative analyst sees the stock reaching $50.

Broker Rating Update on Target Corporation (NYSE:TGT)

Zacks provides analysts with an Average Broker Rating (or ABR), basing it on sell-side recommendations. Shares of Target Corporation (NYSE:TGT) currently have an ABR of 2.96. This is based on a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.  Moving to earnings estimates, for this current fiscal period, Wall Street analysts have projected that the company will post $1.05 earnings per share. This is the current Zacks consensus EPS which was calculated at the time of writing. Analysts will likely revise their estimates leading in to the actual results date.  

taking a look at the most recent period, which closed on 2017-04-30, Target Corporation reported EPS of $1.21 for a surprise factor of 35.96%, calculated by being $0.32 away from analyst projections.

Investors will be marking their calendars for 2017-08-16, when the company is planning to release their quarterly results.

During the most recent trading session, Seattle Genetics, Inc. (NASDAQ:SGEN) shares traded -3.40%. Tracking the stock price in relation to moving averages may provide enhanced perspective on stock performance. After a recent look, the stock has been seen trading $-9.36 off of the 50-day moving average of $63.99 and $-8.48 separated from the 200-day moving average of $63.11. Taking a further look from a different perspective, the stock has been recently recorded -27.51% off of the 52-week high of 75.36 and +52.05% apart from the 52-week low of 35.93. Monitoring stock price activity relative to moving averages and the highs and lows for the past year might help with future stock price value assessment. 

Price Target in Focus

While monitoring stock technicals is important, most investors are more concerned with where the stock might be going now.  Equity research analysts have provided views on where they believe the stock will be trading in the future. According to Thomson Reuters, sell-side analysts are projecting a consensus target price of $58.70 on company shares. This is a near-term estimate for the next 12-18 months.

Currently, Seattle Genetics, Inc. has a price to earnings ratio of N/A. Analysts and investors may also opt to evaluate a company's PEG or price to earnings growth ratio. The stock currently has a PEG Ratio of -0.02.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

By DR Staff Writer

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with MarketBeat's FREE daily email newsletter:

Latest Stories